


LTGO-33

Na_v1.8

state-independent selective Na_v1.8 inhibitor
preclinical for pain disorders
discovery undisclosed

Mol. Pharmacol., January, 2024

LIEBER INSTITUTE / LATIGO BIOTHERAPEUTICS




darovasertib

pan-PKC

oral, first-in-class pan-PKC inhibitor
phase 2/3 for metastatic uveal melanoma
SAR against mutant cell line from AEB071

J. Med. Chem., January, 2024

NOVARTIS, MA / IDEAYA, CA / PFIZER, NY




LY3509754

IL-17A

oral IL-17A inhibitor
phase 1 for psoriasis (disc.)
discovery undisclosed

Clin. Pharmacol. Ther., January, 2024

ELI LILLY, INDIANAPOLIS, IN




CVN766

Ox1R

oral Ox1R antagonist
phase 1 for psychiatric conditions
HTS and opt. for Ox1R selectivity

Bioorganic Med. Chem. Lett., January, 2024

CEREVANCE, UK / TAKEDA CAMBRIDGE, UK




MZ-101

GYS1

oral GYS1 inhibitor
preclinical for Pompe disease
HTS and opt. for GYS1 selectivity

Sci. Transl. Med., January, 2024

MAZE, SO. SAN FRANCISCO, CA




zosurabalpin

LptB₂FGC

IV, bacterial LptB₂FGC complex inhibitor
phase 1 for bacterial infections
whole-cell phenotypic screen of macrocyclic peptides

Nature, January, 2024

HARVARD UNIVERSITY, MA / ROCHE, CH




afuresertib

AKT

oral, ATP-competitive pan-AKT inhibitor
phase 2 for cancers (disc.)
discovery undisclosed

Press Release, January, 2024

GLAXOSMITHKLINE, PA / LAEKNA, CN



ANAVEX 3-71


SIGMAR1 and M1

oral, dual SIGMAR1 and M1 activator
phase 2 for Schizophrenia

from a M1 mAChR and σ1R HT
receptogram profiling

Press Release, January, 2024

IBR, NESS ZIONA, IL / ANAVEX, NEW YORK, NY




exarafenib

pan-RAF

pan-RAF kinase inhibitor
phase 1 for solid tumors
SBDD starting from naporafenib scaffold

J. Med. Chem., January, 2024

KINNATE BIOPHARMA, SAN DIEGO, CA



ORIC-101

GR

GR antagonist
phase 1 for cancers (disc.)
from phenylimidazole and SBDD

Clin Cancer Res, January, 2024

ORIC, SO. SAN FRANCISCO, CA